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Background-—Current literature only reports variable information from single-center studies on the recurrence rate, the
complications, and the outcome of patients with Takotsubo syndrome (TTS) experiencing recurrent TTS. Therefore, a detailed
description of clinical characteristics, predictors, and the prognostic impact of patients with TTS and recurrences in a multicenter
registry is needed.
Methods and Results-—Weanalyzed 749 patients with TTS from9European centers being part of the international, multicenter GEIST
(German Italian Stress Cardiomyopathy) Registry. Patients were divided into the recurrence group and the nonrecurrence group. The
recurrence rate at a median follow-up of 830 days (interquartile range, 118–1701 days) was 4%. Most recurrences were documented
in the first 5 years after the index TTS episode. Up to 2 TTS recurrenceswere documented in 2 of 30 patients (6%). A variable ballooning
pattern (n=6, 0.8%) with, in particular, involvement of the right ventricular occurred in 3 cases (0.4%) at the recurrence event. Except for
the higher presence of arterial hypertension (86.7% versus 68.3%; P=0.03) in the recurrence group, no other baseline characteristics
were different between groups. Observation of TTS complications during follow-up, including stroke, thromboembolic events, in-
hospital death, and cardiogenic shock, revealed no significant differences between groups (P>0.05), except the higher presence of
pulmonary edema in the recurrence group versus the nonrecurrence group (13.3% versus 4.9%; P=0.04).
Conclusions-—The incidence of TTS recurrence is estimated to be 4% in this multicenter TTS registry. A variable TTS pattern at
recurrence is common in up to 20% of recurrence cases. ( J Am Heart Assoc. 2019;8:e010753. DOI: 10.1161/JAHA.118.
010753.)
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T akotsubo syndrome (TTS) is characterized by a transientventricular dysfunction. Patients have symptoms mim-
icking an acute coronary syndrome.1,2 Despite the transient
character of TTS, a significant number of adverse events has
been reported.3 Mainly in the short-term phase of TTS,
patients are experiencing arrhythmias, including sudden
cardiac death,4–6 cardiogenic shock,7 and thromboembolic
events, including stroke.8,9 First, it has been thought that TTS
may affect only the left ventricle (LV), whereas some years
later right ventricular or biventricular involvement has been
also reported.10,11 The recovery of these wall motion abnor-
malities is observed within days to weeks. The following 4
different TTS forms have been reported to date: apical form,
midventricular form, basal form, and rare focal form.12,13 In
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the past decade, different studies have shown that TTS is not
associated with a favorable prognosis, with a mortality rate
comparable to that of acute coronary syndrome.3,14
Current literature reports a recurrence rate of 1% to 6%.15–17
However, these data are inconsistent and frequently limited
by its single-center character. Moreover, it is not known which
patients are at risk for recurrence and if the presence of TTS
recurrences is associated with future cardiovascular events or
mortality. In view of these limitations, we sought to compre-
hensively describe the incidence, clinical characteristics,
predictors, and impact of recurrence in TTS in a large
multicenter European registry.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure; they will be provided on
request to the corresponding author. This multicenter GEIST
(German Italian Stress Cardiomyopathy) Registry included
906 consecutive patients with TTS, enrolled from 9 centers:
University Heart Center L€ubeck (L€ubeck, Germany); Heart
Center Leipzig–University Hospital (Leipzig, Germany); Univer-
sity Medical Center Mannheim (Mannheim, Germany); Univer-
sity Hospital of Foggia (Foggia, Italy); Casa Sollievo della
Sofferenza Hospital (San Giovanni Rotondo, Italy); San Paolo
Hospital (Bari, Italy); University Hospital of Palermo (Palermo,
Italy); University Hospital of Rome “Tor Vergata,” (Rome, Italy);
and University Hospital “Umberto I–Lancisi–Salesi” (Ancona,
Italy). Patients were prospectively included in accordance with
diagnostic criteria for TTS.1 These criteria essentially highlight
transient wall motion abnormality in the LV or right ventricle;
and also describe an event that occurs frequently, but not
always, in the wake of a stressful trigger. Other salient points
mandate the absence of obstructive coronary disease related
to wall motion abnormalities; focus on the appearance of new
electrocardiographic pathological features, which mimic acute
coronary syndrome or modest elevations in cardiac troponin
levels; and underline the absence of pheochromocytoma or
myocarditis in the patient. A ballooning pattern was defined,
according to defined criteria, as being a transient systolic
dysfunction with marked LV contraction abnormality attribu-
table to akinesia or dyskinesia of the LV apical and/or
midventricular or basal segments, extending beyond a single
coronary perfusion bed.12,18
Recurrence of TTS was defined as new wall motion abnor-
malities in the absence of obstructive coronary disease after
recovery of the index TTS events. The recurrence of TTS was
assessed by medical record review and/or telephonic review. If
medical records, treating physicians, patients, or relatives were
able to provide further information about the circumstances of
recurrence, the angiograms, echocardiograms, and ECGs were
independently reviewed by 2 experienced cardiologists (I.E.-B.,
I.A., F.S., F. Gustafierro, N.D.B., T.S., C.M., I.E., G.N., S.N., E.M.,
Francesco Romeo, H.T., F. Guerra, A.C., I.G.) to evaluate the
diagnosis of TTS. The study protocol was approved by the local
Ethics Committee. All methods were performed in accordance
with the relevant guidelines and regulations. The study was
conducted in compliance with the Declaration of Helsinki on
investigations in human subjects. Informed consent waswaived
by the Ethics Committee.
Statistical Analysis
Data are presented asmeansSD for continuous variables with
a normal distribution, median (interquartile range) for continu-
ous variables with a nonnormal distribution, and frequency
(percentage) for categorical variables. TheKolmogorov-Smirnov
test was used to assess normal distribution. The Student t test
and theMann-Whitney U-test were used to compare continuous
variableswith normal andnonnormal distributions, respectively.
The v2 test or Fisher’s exact test was used to compare
categorical variables. The log-rank test was used to compare
Kaplan-Meier survival curves between the cardiopulmonary
failure group and the noncardiopulmonary failure group. Factors
with P<0.10 on univariate analysis were entered into the Cox
multivariate regression todefine independent risk factors for the
end point. Statistical analysis was performed with SPSS 23.0 in
all analyses; P≤0.05 (2 tailed) indicated statistical significance.
Results
Of the 906 consecutive patients included in the GEIST Registry,
follow-up was documented in 749. Baseline characteristics are
illustrated in Table 1. Most patients were postmenopausal
women (90.2%). A stressful event was documented in 70% of
cases, with a predominance of a physical stress trigger (38.7%).
The moderate reduced LV ejection fraction at the index event
(median, 40% [interquartile range, 15%–71%]) was almost
Clinical Perspective
What Is New?
• Takotsubo syndrome (TTS) is associated with a recurrence
rate of 4%.
• A variable TTS pattern at recurrence is common in up to 20%
of recurrence cases.
What Are the Clinical Implications?
• Patients with TTS are at risk of TTS recurrence.
• In patients with a history of TTS and new symptoms
mimicking acute coronary syndrome, physicians should
consider the possibility of recurrent TTS.
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normalized through follow-up (median, 53% [interquartile range,
20%–77%]). Overall, TTS recurrence was documented in 30
patients (4%) at a median follow-up of 830 days (interquartile
range, 118–1701 days; 95% CI, 981–1128 days).
Clinical Characteristics of the Patients With TTS
Recurrence
Patients with TTS who experienced recurrence events tended to
be younger (meanSD, 6813 versus 7011 years; P=0.3).
Cardiovascular risk factors, such as arterial hypertension
(86.7% versus 68.3%; P=0.03), were significantly higher in the
recurrence group. Observing the different TTS forms/ballooning
patterns and the LV ejection fraction at index event and/or
follow-up, there was no difference between both groups. Even
more, further baseline characteristics, includingmalignancy and
current smoking, were not different between both groups. At the
recurrence episode, most patients (n=21) presented with the
apical form, whereas the midventricular form was evident in 7
patients. In our cohort, 20% of patients presented with variable
ballooning at the recurrence episode: 3 patients with an apical
pattern at the index event and a midventricular pattern at the
recurrence event and a further 3 patients with right ventricular
involvement at the recurrence event. Detailed information of
Table 1. Baseline Clinical Characteristics
Variable All Patients (n=749)
Patients With No
Recurrence (n=719)
Patients With
Recurrence (n=30) P Value
Age, y 7010 7011 6813 0.30
Women 676 (90.2) 651 (90.5) 25 (83.3) 0.19
Hypertension 596 (70.1) 491 (68.3) 25 (86.7) 0.03
Current smoking 187 (22.7) 159 (22.1) 10 (33.3) 0.15
Malignancy 123 (13.9) 95 (13.2) 3 (10.0) 0.61
Stressful event 526 (70.2) 505 (70.2) 21 (70.0) 0.98
Emotional 290 (38.7) 281 (39.1) 9 (30.0) 0.31
Physical 238 (31.8) 224 (31.1) 12 (40.0) 0.10
Ballooning pattern
Apical 616 (82.2) 590 (82.4) 26 (86.7) 0.54
Midventricular 134 (17.8) 129 (17.9) 5 (16.7) 0.86
Basal 17 (2.3) 17 (2.4) 0 (0.0) 1.00
Focal 1 (0.1) 1 (0.2) 0 (0.0) 1.00
LVEF, % 40 (15–71) 40 (15–71) 40 (25–59) 0.87
Time of hospitalization, d 8 (1–96) 8 (1–96) 6 (2–16) 0.29
Follow-up LVEF, % 53 (20–77) 53 (20–77) 54 (40–72) 0.58
Data are presented as number (percentage) of patients, meanSD for normal distribution, and median (interquartile range) for nonnormal distribution. P values were calculated for the
comparison between patients with Takotsubo syndrome and recurrence. LVEF indicates left ventricular ejection fraction.
Table 2. In-Hospital Events of Patients With TTS
Variable
All Patients
(n=749)
Patients With
No Recurrence
(n=719)
Patients With
Recurrence (n=30) P Value
Cardiac electronic device implantation 9 (1.2) 9 (1.3) 0 (0.0) 1.00
In-hospital death 19 (2.5) 18 (2.5) 1 (3.3) 0.55
Thromboembolic events 21 (2.8) 20 (2.8) 1 (3.3) 0.58
Stroke 10 (1.3) 9 (1.3) 1 (3.3) 0.34
Cardiogenic shock 59 (7.8) 59 (8.2) 0 (0.0) 0.16
Pulmonary edema 39 (5.2) 35 (4.9) 4 (13.3) 0.04
Data are given as number (percentage) of patients. TTS indicates Takotsubo syndrome.
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triggers of TTS recurrence is illustrated in Table 2. Interest-
ingly, in 14 patients (46%), TTS has been triggered by a new
stressor compared with the first TTS event (9 patients
experienced an emotional trigger, and 5 patients experienced
a physical trigger).
Predictors of Recurrence in TTS and Triggers of
Recurrence
Using univariate Cox regression, no factors were identified as
predictive for TTS recurrence (Table 3).
In-Hospital Events of the Recurrences of Patients
With TTS
Different in-hospital events, including thromboembolic events
(2.8% versus 3.3%), stroke (1.3% versus 3.3%), cardiogenic
shock (8.2% versus 0%), and the use of cardiac electronic
device implantation (1.3% versus 0%), were evaluated
(Table 4). No significant difference was documented between
both groups. Although pulmonary edema was more often
documented in the recurrence group than in the nonrecur-
rence group (13.3% versus 4.9%; P=0.04) at the index event,
the in-hospital mortality and the duration of hospital stay did
not differ between both groups. Of 30 patients, 2 (6%)
developed an in-hospital TTS recurrence.
Follow-Up Data Treatment and Clinical Outcome
The earliest time of recurrence was 8 days, and the latest
time of recurrence was 2555 days. The Figure presents the
recurrence-free survival of patients with TTS. Except for 2
patients with 2 recurrences, only 1 recurrence event was
documented in all other patients.
Information about drugs at admission and discharge was
documented in 22 patients experiencing a recurrence. At
admission, these drugs included a b blocker (54%, n=12),
an angiotensin-converting enzyme (ACE) inhibitor or AT
(angiotensin-converting-enzyme)-II antagonist (36.6%, n=11),
and a combination of a b blocker and an ACE inhibitor or AT-II
antagonist (20%, n=6); and at discharge, these drugs included
a b blocker (50%, n=15), an ACE inhibitor or AT-II antagonist
(54%, n=12), and a combination of a b blocker and an ACE
inhibitor or AT-II antagonist (33.3%, n=10).
Table 3. Trigger Factors of Recurrence Episode of 30 TTS
Cases
Case No. No. of Recurrences Physical Stressor Emotional Stressor
1 1  
2 1  +
3 1 Not documented Not documented
4 1  
5 1 + 
6 1  +
7 1  +
8 1  +
9 1  
10 1  +
11 2  
12 1  +
13 1 + 
14 1  
15 1 + 
16 1  +
17 1 + 
18 2 + +
19 1 + 
20 2 + 
21 1 + 
22 1 Not documented Not documented
23 1 + 
24 1 Not documented Not documented
25 1 Not documented Not documented
26 1  
27 1  +
28 1  +
29 1  +
30 1  
+ Indicates yes; , no; TTS, Takotsubo syndrome.
Table 4. Predictors of Recurrence in TTS
Variable
Univariate
Hazard Ratio (95% CI) P Value
Diabetes mellitus 0.52 (0.15–1.73) 0.289
Age, y 0.99 (0.96–1.02) 0.700
Men 2.44 (0.93–6.38) 0.069
Current smoking 1.51 (0.71–3.19) 0.276
Hypertension 2.37 (0.82–6.79) 0.109
Malignancy 0.83 (0.25–2.74) 0.760
Physical trigger 0.72 (0.33–1.60) 0.431
Emotional trigger 1.20 (0.57–2.50) 0.622
Apical ballooning 2.10 (0.73–6.05) 0.165
Initial LVEF, % 0.98 (0.95–1.02) 0.467
Cardiogenic shock 0.55 (0.07–4.09) 0.564
LVEF indicates left ventricular ejection fraction; TTS, Takotsubo syndrome.
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Discussion
The present European multicenter TTS registry is one of the
largest TTS cohorts reported yet. The main results of this study
focusing on TTS recurrences are as follows: (1) the recurrence
rate of TTS is 4%, with a predominance of a single recurrence
event; (2) a variable TTS pattern at recurrence is common in up
to 20% of recurrence cases; and (3) most clinical baseline
characteristics and in-hospital complications are comparable
between the recurrence and nonrecurrence group.
Incidence of TTS Recurrence
In the present large multicenter study, we describe a
recurrence rate of 4.0% during a median follow-up of
830 days (interquartile range, 118–1701 days). The recur-
rence rate of TTS has been estimated to be between 1% and
11.4% in single-center studies and meta-analyses.11,15–17,19–22
Although, previous studies have commented on the recur-
rence rate of TTS, these studies have had a single-center
character with a low number of patients and variable
information. Our study investigates in depth the characteris-
tics of patients with TTS experiencing recurrence. Overall, it
shows that most baseline characteristics, except arterial
hypertension, and in-hospital events might be similar in the
recurrence and nonrecurrence groups of patients with TTS.
The mechanism of recurrence in TTS remains unclear. A
genetic predisposition is still debated.23
Interestingly, our data, for the first time, demonstrate that
in up to 20% of recurrence cases, a variable TTS pattern is
presented. In addition, 46% of patients have had a new stress
trigger at TTS recurrence. This observation has been reported
elsewhere in small case series of TTS.19 In our study, 3
patients with TTS (10%) showed a right ventricular involve-
ment at the recurrence event and 3 patients (10%) with the
apical form at initial TTS presented a midventricular TTS form
at the recurrence event. This could not be explained by the
proposed theory of TTS association with the gradient of b
receptors. Although myocardial responsiveness to adrenergic
stimulation is increased in the apical region, norepinephrine
content is lower in the apex than in the base.24 Another
proposed hypothesis is that a previous episode of TTS form
may protect this region of TTS involved in the TTS recurrence,
with a higher vulnerability of other regions. However, we
demonstrate, consistent with other reports, that there are
recurrent cases of TTS with the same ballooning pattern,
similar to the index event.12
Drug Therapy and Recurrence
Another interesting data point is that 2 patients (0.26%)
experienced 2 recurrence episodes, and the highest number of
recurrences was observed at an early time (up to 5 years) after
the initial TTS event. It could be speculated that the
myocardium remains vulnerable at this first stage after
the first TTS event. Another possible explanation could be that
the prescription of drugs, including b blockers, could be
abandoned by patients and physicians after the first TTS event.
In our study, >50% of patients were admitted with a b blocker,
an ACE inhibitor, or an AT-II antagonist. Although TTS is
associated with hyperadrenergic stimulation, the ACE inhibitor
or AT-II antagonist was more able to reduce the recurrence rate
than b blockers15,25–27 in nonrandomized trials. Moreover, a
combined treatment might be more effective than stand-alone
treatment.27 A combination of a b blocker and ACE inhibitor or
AT-II antagonist was documented in 28% of recurrence cases.
This might increase the speculation that a combined treatment
is more effective. A possible explanation is that a reduction in
sympathetic activity through interaction with the renin-
angiotensin system or suppression inflammatory reactions on
the myocardium is more effective on the combined treatment
than on stand-alone treatment.
Finally, because our data are presenting that >50% of
patients with TTS at the recurrence event are admitted with a
b blocker, an ACE inhibitor or AT-II antagonist, or a
combination of a b blocker and an ACE inhibitor or AT-II
antagonist, this might raise the question of what is the
optimal treatment strategy to avoid recurrences in TTS. This
issue should be evaluated in future well-designed prospective
randomized trials.
Limitations
Despite the multicenter character of the current study and high
number of patients, the analysis has some limitations. First, it is
a registry-based design with differences on the recorded
parameters between centers. Some data are missing, such as
Figure. Recurrence-free survival presents that most recurrences
are common the first years after a Takotsubo syndrome event.
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the compliance of patients regarding drug treatment after the
index event. In addition, the duration of medical treatment
could not be evaluated because of the small number of
recurrences. However, the current report is the largest report of
patients with TTS recurrence. Mortality analysis is not mean-
ingful because of the low number of observations.
Conclusions
The recurrence rate of TTS is 4% in this multicenter registry.
Up to 2 recurrences could be documented in patients with
TTS and variable patterns. A variable TTS pattern at
recurrence is documented in up to 20% of recurrence cases.
In the present study, no predictors could be identified for
recurrence of TTS.
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